Subscribe

|Articles|March 20, 2023

PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023

AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles.

In an interview with Pharma Commerce Editor, Nicholas Saraceno, Corey Ford, VP of reimbursement & policy insight, AmerisourceBergen, desribes his experience in combating reimbursement challenges at Access PAP 2023.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Related Content

Ozempic Insulin injection pen or insulin cartridge pen for diabetics and weight loss. | © Kassandra - stock.adobe.com (1142156500)

FAQ: What Does the Medicare GLP-1 Bridge Mean for Pharma?

ByStephen Appezzato

June 5th 2026

Danny Williams

How Pharma 3PLs Are Rethinking Their Role in Drug Commercialization

ByDanny Williams,Stephen Appezzato

June 4th 2026

Wegovy Pill's UAE Debut Is a Distribution Story, Not Just a Market Entry

ByStephen Appezzato

June 3rd 2026

Erez Israeli, chief executive officer, Dr. Reddy’s Laboratories.

Q&A: Dr. Reddy's CEO on Generic Semaglutide and the GLP-1 Market Ahead

ByErez Israeli ,Stephen Appezzato

June 3rd 2026

Cencora headquarters in Conshohocken, Pennsylvania, USA, on November 6, 2023. Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company. | © JHVE Photo -stock.adobe.com (678450429)

Cencora-Kite Agreement Signals CGT Commercialization Shift

ByStephen Appezzato

June 2nd 2026

Trending on Pharmaceutical Commerce

FAQ: What Does the Medicare GLP-1 Bridge Mean for Pharma?

Q&A: Why Pharma Supply Chains Are Turning to AI

FAQ: The Medicare GLP-1 Bridge Program

Pharma Pulse: 340B Uncertainty, Drug Shortages, and Wegovy's Global Debut

Cencora-Kite Agreement Signals CGT Commercialization Shift